Selected research
Industry Research
Orally Administered Vaccine Industry Research Report 2026
Market perspective
The global Orally Administered Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Orally Administered Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Orally Administered Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Orally Administered Vaccine include Lanzhou Institute, Sanofi, Merck, GSK, Tiantan Biological, Valneva, Vabiotech, Shanghai United Cell and Serum Institute, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Orally Administered Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Orally Administered Vaccine Market by Company
Lanzhou Institute
Sanofi
Merck
GSK
Tiantan Biological
Valneva
Vabiotech
Shanghai United Cell
Serum Institute
PaxVax
Panacea Biotec Ltd
Halfkin Bio-Pharmaceuticals
EuBiologics
Bio-Med
Bibcol
Orally Administered Vaccine Segment by Type
Rotavirus Vaccine
Oral Polio Vaccine
Cholera Vaccine
Other
Orally Administered Vaccine Segment by Application
Public
Private
Orally Administered Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orally Administered Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Orally Administered Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orally Administered Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Orally Administered Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Orally Administered Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Orally Administered Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rotavirus Vaccine
- Oral Polio Vaccine
- Cholera Vaccine
- Other
Applications
- Public
- Private
Companies covered
- Lanzhou Institute
- Sanofi
- Merck
- GSK
- Tiantan Biological
- Valneva
- Vabiotech
- Shanghai United Cell
- Serum Institute
- PaxVax
- Panacea Biotec Ltd
- Halfkin Bio-Pharmaceuticals
- EuBiologics
- Bio-Med
- Bibcol
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Orally Administered Vaccine Market Size (2021-2032)
- 2.2.2 Global Orally Administered Vaccine Sales (2021-2032)
- 2.2.3 Global Orally Administered Vaccine Market Average Price (2021-2032)
- 2.3 Orally Administered Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rotavirus Vaccine
- 2.3.3 Oral Polio Vaccine
- 2.3.4 Cholera Vaccine
- 2.3.5 Other
- 2.4 Orally Administered Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Public
- 2.4.3 Private
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Orally Administered Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Orally Administered Vaccine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Orally Administered Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Orally Administered Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Orally Administered Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Orally Administered Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Orally Administered Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Orally Administered Vaccine, Established Date
- 3.9 Global Orally Administered Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Lanzhou Institute
- 4.1.1 Lanzhou Institute Company Information
- 4.1.2 Lanzhou Institute Business Overview
- 4.1.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Lanzhou Institute Orally Administered Vaccine Product Portfolio
- 4.1.5 Lanzhou Institute Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Orally Administered Vaccine Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Orally Administered Vaccine Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 GSK
- 4.4.1 GSK Company Information
- 4.4.2 GSK Business Overview
- 4.4.3 GSK Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GSK Orally Administered Vaccine Product Portfolio
- 4.4.5 GSK Recent Developments
- 4.5 Tiantan Biological
- 4.5.1 Tiantan Biological Company Information
- 4.5.2 Tiantan Biological Business Overview
- 4.5.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Tiantan Biological Orally Administered Vaccine Product Portfolio
- 4.5.5 Tiantan Biological Recent Developments
- 4.6 Valneva
- 4.6.1 Valneva Company Information
- 4.6.2 Valneva Business Overview
- 4.6.3 Valneva Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Valneva Orally Administered Vaccine Product Portfolio
- 4.6.5 Valneva Recent Developments
- 4.7 Vabiotech
- 4.7.1 Vabiotech Company Information
- 4.7.2 Vabiotech Business Overview
- 4.7.3 Vabiotech Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Vabiotech Orally Administered Vaccine Product Portfolio
- 4.7.5 Vabiotech Recent Developments
- 4.8 Shanghai United Cell
- 4.8.1 Shanghai United Cell Company Information
- 4.8.2 Shanghai United Cell Business Overview
- 4.8.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shanghai United Cell Orally Administered Vaccine Product Portfolio
- 4.8.5 Shanghai United Cell Recent Developments
- 4.9 Serum Institute
- 4.9.1 Serum Institute Company Information
- 4.9.2 Serum Institute Business Overview
- 4.9.3 Serum Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Serum Institute Orally Administered Vaccine Product Portfolio
- 4.9.5 Serum Institute Recent Developments
- 4.10 PaxVax
- 4.10.1 PaxVax Company Information
- 4.10.2 PaxVax Business Overview
- 4.10.3 PaxVax Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 PaxVax Orally Administered Vaccine Product Portfolio
- 4.10.5 PaxVax Recent Developments
- 4.11 Panacea Biotec Ltd
- 4.11.1 Panacea Biotec Ltd Company Information
- 4.11.2 Panacea Biotec Ltd Business Overview
- 4.11.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio
- 4.11.5 Panacea Biotec Ltd Recent Developments
- 4.12 Halfkin Bio-Pharmaceuticals
- 4.12.1 Halfkin Bio-Pharmaceuticals Company Information
- 4.12.2 Halfkin Bio-Pharmaceuticals Business Overview
- 4.12.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio
- 4.12.5 Halfkin Bio-Pharmaceuticals Recent Developments
- 4.13 EuBiologics
- 4.13.1 EuBiologics Company Information
- 4.13.2 EuBiologics Business Overview
- 4.13.3 EuBiologics Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 EuBiologics Orally Administered Vaccine Product Portfolio
- 4.13.5 EuBiologics Recent Developments
- 4.14 Bio-Med
- 4.14.1 Bio-Med Company Information
- 4.14.2 Bio-Med Business Overview
- 4.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bio-Med Orally Administered Vaccine Product Portfolio
- 4.14.5 Bio-Med Recent Developments
- 4.15 Bibcol
- 4.15.1 Bibcol Company Information
- 4.15.2 Bibcol Business Overview
- 4.15.3 Bibcol Orally Administered Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Bibcol Orally Administered Vaccine Product Portfolio
- 4.15.5 Bibcol Recent Developments
5 Global Orally Administered Vaccine Market Scenario by Region
- 5.1 Global Orally Administered Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Orally Administered Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Orally Administered Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Orally Administered Vaccine Sales by Region: 2027-2032
- 5.3 Global Orally Administered Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Orally Administered Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Orally Administered Vaccine Revenue by Region: 2027-2032
- 5.4 North America Orally Administered Vaccine Market Facts & Figures by Country
- 5.4.1 North America Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Orally Administered Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Orally Administered Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Orally Administered Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Orally Administered Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Orally Administered Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Orally Administered Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Orally Administered Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Orally Administered Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Orally Administered Vaccine Market Facts & Figures by Country
- 5.7.1 South America Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Orally Administered Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Orally Administered Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Orally Administered Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Orally Administered Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Orally Administered Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Orally Administered Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Orally Administered Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Orally Administered Vaccine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Orally Administered Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Orally Administered Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Orally Administered Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Orally Administered Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Orally Administered Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Orally Administered Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Orally Administered Vaccine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Orally Administered Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Orally Administered Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Orally Administered Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Orally Administered Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Orally Administered Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Orally Administered Vaccine Value Chain Analysis
- 8.1.1 Orally Administered Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Orally Administered Vaccine Production Mode & Process
- 8.2 Orally Administered Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Orally Administered Vaccine Distributors
- 8.2.3 Orally Administered Vaccine Customers
9 Global Orally Administered Vaccine Analyzing Market Dynamics
- 9.1 Orally Administered Vaccine Industry Trends
- 9.2 Orally Administered Vaccine Industry Drivers
- 9.3 Orally Administered Vaccine Industry Opportunities and Challenges
- 9.4 Orally Administered Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst